Stimulant Dependence



Central nervous system stimulants are a class of drugs that speed up physical and mental processes. They include the amphetamines, cocaine, methylphenidate, phentermine, modafinil, bath salts, flakka, and caffeine.


Prevalence Amphetamines Methamphetamine Cocaine Methylphenidate Phentermine Modafinil Bath salts Flakka Caffeine Abstinence syndrome 


  1. 1.
    National survey on drug use and health: trends in prevalence of various drugs for ages 12 or older, ages 12 to 17, ages 18 to 25, and ages 26 or older. National Institute on Drug Abuse (NIDA). 2015.
  2. 2.
    Amphetamines. Center for Substance Abuse Research (CESAR)/University of Maryland.
  3. 3.
    Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady. Michigan News/University of Michigan. December 15, 2008.
  4. 4.
    Dubuc B. The brain from top to bottom. McGill University. May 2012.
  5. 5.
    Christian L. Drugs of abuse. In: Katzung BG, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill Education; 2014. p. 552–6.Google Scholar
  6. 6.
    O’Brien RC. The encyclopedia of drug abuse. Facts on File: New York; 1984.Google Scholar
  7. 7.
    Wilford BB, editor. Major drugs of abuse. In: Drug abuse: a guide for the primary care physician. Chicago: American Medical Association; 1981. p. 21–84.Google Scholar
  8. 8.
    Shlafer M, Marieb EN. Substance use and misuse. In: The nurse, pharmacology and drug therapy. Redwood City: Addison-Wesley; 1989. p. 509–28.Google Scholar
  9. 9.
    Anglin MD, Perrochet B, Burke C, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoact Drugs. 2011:137–41.Google Scholar
  10. 10.
    Methamphetamine. Center for Substance Abuse Research (CESAR)/University of Maryland.
  11. 11.
    Methamphetamine. National Institute on Drug Abuse (NIDA). February 2017.
  12. 12.
    Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76(8):1169–74.PubMedGoogle Scholar
  13. 13.
    Handly N. Amphetamine toxicity. Medscape. December 16, 2016.Google Scholar
  14. 14.
    Tennant FS. Cocaine withdrawal step by step. Emergency Medicine. 1987;65–68.Google Scholar
  15. 15.
    Milhorn HT. Chemical dependence: diagnosis, treatment, and prevention. New York: Springer; 1990.CrossRefGoogle Scholar
  16. 16.
    Vereby K, Gold MS. From coca leaves to crack: the effects of dose and routes of administration on abuse liability. Psychiatr Ann. 1988;18:513–20.CrossRefGoogle Scholar
  17. 17.
    Wyatt RJ, Karourn F, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatr Ann. 1988;18:531–4.Google Scholar
  18. 18.
    Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW, editors. Principles of pharmacology: the pathophysiological basis of drug therapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer; 2011.Google Scholar
  19. 19.
    Gold M. Crack abuse: its implications and outcomes. Resid Staff Physician. 1987;33:45–53.Google Scholar
  20. 20.
    Bouknight LG. Cocaine – a particularly addicting drug. Postgrad Med. 1988;83:115–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Gottheil E, Weinstein SP. Cocaine risks: a review. Fam Pract Recertification. 1983;5:78–90.Google Scholar
  22. 22.
    Garvin FH. Chronic neuropharmacology of cocaine: progress in pharmacotherapy. J Clin Psychiatry. 1988;49:11–6.Google Scholar
  23. 23.
    Dackis CA, Gold MS. Psychopharmacology of cocaine. Psychiatr Ann. 1988;18:528–30.CrossRefGoogle Scholar
  24. 24.
    The health effects of cocaine use and abuse: short-term and long-term effects. VeryWell. November 16, 2016.
  25. 25.
    DrugFacts: cocaine. National Institute on Drug Abuse (NIDA). June 2016.
  26. 26.
    Cregler LL, Mark H. Medical complications of cocaine abuse. N Engl J Med. 1986;345:1495–500.CrossRefGoogle Scholar
  27. 27.
    Miller GW. The cocaine habit. Am Fam Physician. 1985;31:173–6.PubMedGoogle Scholar
  28. 28.
    Bouknight LG. Cocaine – a particularly addicting drug. Postgrad Med. 1988;83:115–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Brower KJ, Paredes A. Cocaine withdrawal. Arch Gen Psychiatry. 1987;44(3):297–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Dittmar PK, Olmedo R. An evidence-based approach to cocaine-associated emergencies. Emerg Med. 2008;10(1):1–20.Google Scholar
  31. 31.
    Dwyer BJ, editor. Cocaine: helping patients avoid the end of the line. Emerg Med Rep. 1985;6:17–26.Google Scholar
  32. 32.
    Ritalin. Center for Substance Abuse Research (CESAR). University of Maryland. 2013.
  33. 33.
    Ritalin Fast Facts. National Drug Intelligence Center (NDIC). September 2003.
  34. 34.
    Methylphenidate. MedlinePlus. February 15, 2016.
  35. 35.
    Phentermine. 2015.
  36. 36.
    Biaggioni I, Roberson D. Adrenoceptor agonists and sympathomimetic drugs. In: Bertram GK, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill; 2015.Google Scholar
  37. 37.
    The effects of bath salts use. Drug Abuse.
  38. 38.
    Glatter R. Flakka: the new designer drug you need to know about. Forbes. April 4, 2015.
  39. 39.
    Caffeine content for coffee, tea, soda and more. Mayo Clinic. May 13, 2014.
  40. 40.
    Kotz D. FDA warns against dangers of caffeine powder. Boston Globe. July 23, 2014.Google Scholar
  41. 41.
    Gilbert SG. Caffeine. Toxipedia. June 13, 2012.
  42. 42.
    DSM-5. Diagnostic and statistical manual of mental disorder. In: American Psychiatric Association. 5th ed. Arlington: American Psychiatric Publishing; 2013.Google Scholar
  43. 43.
  44. 44.
    Schueler SJ, Beckett JH, Gettings DS. Caffeine overdose. Treatment. FreeMD. May 23, 2011.

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.East Central HealthNet Family Medicine Residency ProgramMeridianUSA
  2. 2.University of Mississippi School of MedicineJacksonUSA

Personalised recommendations